Prevalence (%) with 95% confidence interval of the GOLD severity stages* for the countries participating in the European Community Respiratory Health Survey
| Stage 0 (n = 1751) | Stage I (n = 369) | Stages II–III (n = 168) | |
|---|---|---|---|
| *Eight subjects were in stage III and there were no patients in stage IV. | |||
| Spain | 23.7 (21.6 to 26.0) | 1.6 (1.0 to 2.4) | 1.1 (0.6 to 1.7) |
| France | 9.2 (7.9 to 10.5) | 1.0 (0.6 to 1.6) | 0.5 (0.3 to 1.0) |
| Italy | 10.4 (8.3 to 12.8) | 0.9 (0.4 to 1.9) | 0.4 (0.1 to 1.1) |
| Switzerland | 10.4 (8.3 to 12.8) | 7.4 (5.6 to 9.5) | 2.3 (1.3 to 3.6) |
| Germany | 11.1 (9.6 to 12.7) | 2.4 (1.7 to 3.2) | 1.3 (0.8 to 2.0) |
| Belgium | 11.7 (9.5 to 14.4) | 3.4 (2.2 to 5.1) | 2.4 (1.4 to 3.9) |
| The Netherlands | 8.0 (6.6 to 9.6) | 2.6 (1.8 to 3.6) | 0.9 (0.4 to 1.5) |
| Denmark | 12.5 (8.9 to 16.8) | 4.4 (2.4 to 7.4) | 3.4 (1.6 to 6.1) |
| Sweden | 11.8 (10.2 to 13.5) | 2.3 (1.6 to 3.2) | 0.6 (0.3 to 1.1) |
| Norway | 8.4 (6.7 to 10.4) | 1.1 (0.5 to 2.1) | 1.6 (0.9 to 2.7) |
| Iceland | 11.0 (8.4 to 14.0) | 0.8 (0.2 to 1.9) | 1.1 (0.4 to 2.5) |
| Ireland | 18.9 (14.6 to 23.8) | 4.0 (2.1 to 7.0) | 1.3 (0.4 to 3.4) |
| UK | 9.8 (8.0 to 11.8) | 2.3 (1.4 to 3.4) | 1.0 (0.5 to 1.9) |
| USA | 16.2 (12.6 to 20.3) | 4.0 (2.2 to 6.5) | 0.8 (0.2 to 2.3) |
| Australia | 7.2 (5.2 to 9.7) | 4.3 (2.8 to 6.4) | 1.4 (0.6 to 2.8) |
| New Zealand | 10.6 (8.6 to 12.9) | 3.7 (2.5 to 5.2) | 1.0 (0.5 to 2.0) |
| Total | 11.8 (11.3 to 12.3) | 2.5 (2.2 to 2.7) | 1.1 (1.0 to 1.3) |